AKILI INC (AKLI)
US00974B1070 - Common Stock
Overall AKLI gets a fundamental rating of 2 out of 10. We evaluated AKLI against 40 industry peers in the Health Care Technology industry. While AKLI seems to be doing ok healthwise, there are quite some concerns on its profitability. AKLI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AKLI has reported negative net income.
AKLI had a negative operating cash flow in the past year.
1.2 Ratios
The Return On Assets of AKLI (-74.02%) is worse than 69.23% of its industry peers.
With a Return On Equity value of -101.65%, AKLI perfoms like the industry average, outperforming 43.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.02% | ||
| ROE | -101.65% | ||
| ROIC | N/A |
ROA(3y)-81.25%
ROA(5y)N/A
ROE(3y)-103.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AKLI has a Gross Margin (51.35%) which is comparable to the rest of the industry.
AKLI's Gross Margin has declined in the last couple of years.
AKLI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.35% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.94%
GM growth 5YN/A
2. Health
2.1 Basic Checks
AKLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AKLI has more shares outstanding
Compared to 1 year ago, AKLI has a worse debt to assets ratio.
2.2 Solvency
AKLI has an Altman-Z score of -5.94. This is a bad value and indicates that AKLI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -5.94, AKLI is doing worse than 84.62% of the companies in the same industry.
AKLI has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
AKLI has a better Debt to Equity ratio (0.09) than 64.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.94 |
ROIC/WACCN/A
WACC11.59%
2.3 Liquidity
AKLI has a Current Ratio of 6.02. This indicates that AKLI is financially healthy and has no problem in meeting its short term obligations.
AKLI has a Current ratio of 6.02. This is amongst the best in the industry. AKLI outperforms 87.18% of its industry peers.
AKLI has a Quick Ratio of 6.02. This indicates that AKLI is financially healthy and has no problem in meeting its short term obligations.
AKLI has a better Quick ratio (6.02) than 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.02 | ||
| Quick Ratio | 6.02 |
3. Growth
3.1 Past
AKLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -217.00%.
The Revenue has grown by 424.38% in the past year. This is a very strong growth!
Measured over the past years, AKLI shows a very negative growth in Revenue. The Revenue has been decreasing by -24.76% on average per year.
EPS 1Y (TTM)-217%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q35.29%
Revenue 1Y (TTM)424.38%
Revenue growth 3Y-24.76%
Revenue growth 5YN/A
Revenue growth Q2Q236.28%
3.2 Future
The Earnings Per Share is expected to grow by 5.00% on average over the next years.
AKLI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 194.84% yearly.
EPS Next Y19.97%
EPS Next 2Y13.06%
EPS Next 3Y8.08%
EPS Next 5Y5%
Revenue Next Year97.24%
Revenue Next 2Y74.09%
Revenue Next 3Y66.56%
Revenue Next 5Y194.84%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AKLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AKLI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.06%
EPS Next 3Y8.08%
5. Dividend
5.1 Amount
AKLI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AKILI INC
NASDAQ:AKLI (5/17/2024, 7:00:00 PM)
After market: 0.4148 -0.01 (-2.54%)0.4256
-0.01 (-1.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap33.45M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -74.02% | ||
| ROE | -101.65% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 51.35% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.02 | ||
| Quick Ratio | 6.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-217%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y19.97%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)424.38%
Revenue growth 3Y-24.76%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y